Lung transplantation at the turn of the century

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 185-201

  DeMeo, D L ^a   Ginns, L C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Allograft; Immunosuppression; Infection; Rejection; Survival

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE;

CANCER RECURRENCE; CANCER RISK; CYTOMEGALOVIRUS INFECTION; EXERCISE TOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUNG DISEASE; LUNG TRANSPLANTATION; MYCOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STANDARDIZATION; SURVIVAL RATE;

FORECASTING; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INFECTION CONTROL; LUNG TRANSPLANTATION; PATIENT SELECTION; QUALITY OF LIFE; SURVIVAL ANALYSIS; TISSUE AND ORGAN PROCUREMENT;

EID: 0035127173     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.185     Document Type: Review

References (109)

1. International guidelines for the selection of lung transplant candidates
2. Coronary artery disease in potential lung transplant recipients greater than 50 years old: The role of coronary intervention
3. Bone loss and fracture after lung transplantation
4. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease
5. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs
6. Maximizing the utilization of donor organs offered for lung transplantation
7. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes?
8. Single- versus double-lung transplantation for pulmonary hypertension
9. Extracorporeal membrane oxygenation support for single-lung transplantation in patients with primary pulmonary hypertension
10. Postoperative independent lung ventilation in a single-lung transplant recipient
11. Living donor lobar lung transplantation: The pediatric experience
12. Recipient and donor outcomes in living related and unrelated lobar transplantation
13. Acute pulmonary edema after lung transplantation: The pulmonary reimplantation response
14. Acute lung injury in lung allografts
15. Primary graft failure following lung transplantation
16. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients
17. Inhaled nitric oxide reduces human lung allograft dysfunction
18. Management of dysfunction in the transplanted lung: Experience with 7 clinical cases. Washington University Lung Transplant Group
19. Early and late airway complications after lung transplantation: Incidence and management
20. Use of balloon-expandable metallic stents in the management of bronchial stenosis and bronchomalacia after lung transplantation
21. Improved airway healing after lung transplantation. An analysis of 348 bronchial stenosis and bronchomalacia after lung transplantation
22. Endoscopic management of bronchial stenosis after double lung transplantation
23. Hyperacute rejection following lung transplantation
24. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings
25. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation
26. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation
27. The radiographic appearances of infection and acute rejection of the lung after heart-lung transplantation
28. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation
29. Limitations of spirometry in detecting rejection after single-lung transplantation
30. Eosinophilic alveolitis in BAL after lung transplantation
31. Exhaled nitric oxide correlates with experimental lung transplant rejection
32. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients
33. The role of transbronchial biopsies in the management of lung transplant recipients
34. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts
35. Improved results of lung transplantation for patients with cystic fibrosis
36. Graft vessel disease and obliterative bronchiolitis after heart/lung transplantation in children
37. Bronchiolitis obliterans syndrome: Incidence, natural history, prognosis, and risk factors
38. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation
39. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group
40. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation
41. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation
42. Staging of bronchiolitis obliterans syndrome using home spirometry
43. Bronchiolitis obliterans after lung transplantation: Findings at chest radiography and high-resolution CT. The Toronto Lung Transplant Group
44. Bronchiolitis obliterans in heartlung transplantation patients: Radiologic findings in 11 patients
45. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management
46. Stanford experience with obliterative bronchiolitis after lung and heartlung transplantation
47. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation
48. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome
49. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis
50. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation
51. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients
52. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome
53. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies
54. New immunosuppressive regimens in lung transplantation
55. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation
56. Clinical trial of tacrolimus versus cyclosporine in lung transplantation
57. Optimization of the immunosuppressive protocol after lung transplantation
58. Suggested guidelines for the use of tacrolimus in lung-transplant recipients
59. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: Results of a randomized, prospective study
60. Induction immunosuppression for lung transplantation with OKT3
61. Infectious complications in heart-lung transplantation. Analysis of 200 episodes
62. Pulmonary transplantation. Early and late results. The Toronto Lung Transplant Group
63. Pulmonary reflexes after human heart-lung transplantation
64. Mucociliary function after lung transplantation
65. Infection after lung transplantation
66. Respiratory syncytial virusassociated infections in adult recipients of solid organ transplants
67. Late fatal adenovirus pneumonitis in a lung transplant recipient
68. Cytomegalovirus infection in heartlung transplant recipients: Risk factors, clinical associations, and response to treatment
69. Viral pulmonary infections in thoracic and cardiovascular surgery
70. Cytomegalovirus infection and survival in lung transplant recipients
71. Infectious complications in pulmonary allograft recipients
72. Opportunities for diagnosing cytomegalovirus in pulmonary infections
73. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation
74. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
75. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: A review of experience in one center
76. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
77. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients
78. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group
79. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis
80. Kaposi's sarcoma after lung transplantation in a Sephardic Jewish woman
81. Incidence and treatment of neoplasia after transplantation
82. Post-transplant acute myeloid leukemia (PT-AML)
83. Recurrence of bronchioloalveolar carcinoma in transplanted lungs
84. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression
85. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients
86. Analysis of Epstein-Barr virusassociated posttransplantation lymphoproliferative disorder after lung transplantation
87. Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation
88. Treatment of posttransplant lymphoproliferafive disease with rituximab monoclonal antibody after lung transplantation
89. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease
90. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
91. Single or bilateral lung transplantation for chronic obstructive pulmonary disease
92. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease
93. The role of cardiopulmonary exercise testing in lung and heart-lung transplantation
94. Hemodynamic responses to exercise after lung transplantation
95. Cardiopulmonary function at maximum tolerable constant work rate exercise following human heart-lung transplantation
96. Maximal exercise testing in single and double lung transplant recipients
97. Exercise performance after lung transplantation
98. Cardiopulmonary exercise testing before and after lung and heart-lung transplantation
99. Respiratory and limb muscle function in lung allograft recipients
100. Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation
101. Determinants of abnormal maximum oxygen uptake after lung transplantation for chronic obstructive pulmonary disease
102. Metabolic myopathy as a cause of the exercise limitation in lung transplant recipients
103. Abnormal skeletal muscle oxidative capacity after lung transplantation by 31P-MRS
104. Skeletal muscle dysfunction in lung transplantation
105. The effect of lung transplantation on health-related quality of life: A longitudinal study
106. Measurement of health-related quality of life before and after heart-lung transplantation
107. Heart-lung transplantation for endstage respiratory disease in patients with cystic fibrosis at Papworth Hospital
108. Long-term health status and quality of life outcomes of lung transplant recipients